Cargando…

Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms

Accumulating evidence suggests that many cancers, including BRCA1- and BRCA2-associated breast cancers, are deficient in DNA repair processes. Both hereditary and sporadic breast cancers have been found to have significant downregulation of repair factors. This has provided opportunities to exploit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowe, Bryan P, Glazer, Peter M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879573/
https://www.ncbi.nlm.nih.gov/pubmed/20459590
http://dx.doi.org/10.1186/bcr2566
_version_ 1782181947869495296
author Rowe, Bryan P
Glazer, Peter M
author_facet Rowe, Bryan P
Glazer, Peter M
author_sort Rowe, Bryan P
collection PubMed
description Accumulating evidence suggests that many cancers, including BRCA1- and BRCA2-associated breast cancers, are deficient in DNA repair processes. Both hereditary and sporadic breast cancers have been found to have significant downregulation of repair factors. This has provided opportunities to exploit DNA repair deficiencies, whether acquired or inherited. Here, we review efforts to exploit DNA repair deficiencies in tumors, with a focus on breast cancer. A variety of agents, including PARP (poly [ADP-ribose] polymerase) inhibitors, are currently under investigation in clinical trials and available results will be reviewed.
format Text
id pubmed-2879573
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28795732010-10-30 Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms Rowe, Bryan P Glazer, Peter M Breast Cancer Res Review Accumulating evidence suggests that many cancers, including BRCA1- and BRCA2-associated breast cancers, are deficient in DNA repair processes. Both hereditary and sporadic breast cancers have been found to have significant downregulation of repair factors. This has provided opportunities to exploit DNA repair deficiencies, whether acquired or inherited. Here, we review efforts to exploit DNA repair deficiencies in tumors, with a focus on breast cancer. A variety of agents, including PARP (poly [ADP-ribose] polymerase) inhibitors, are currently under investigation in clinical trials and available results will be reviewed. BioMed Central 2010 2010-04-30 /pmc/articles/PMC2879573/ /pubmed/20459590 http://dx.doi.org/10.1186/bcr2566 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Review
Rowe, Bryan P
Glazer, Peter M
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
title Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
title_full Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
title_fullStr Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
title_full_unstemmed Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
title_short Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
title_sort emergence of rationally designed therapeutic strategies for breast cancer targeting dna repair mechanisms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879573/
https://www.ncbi.nlm.nih.gov/pubmed/20459590
http://dx.doi.org/10.1186/bcr2566
work_keys_str_mv AT rowebryanp emergenceofrationallydesignedtherapeuticstrategiesforbreastcancertargetingdnarepairmechanisms
AT glazerpeterm emergenceofrationallydesignedtherapeuticstrategiesforbreastcancertargetingdnarepairmechanisms